IL6 and COVID-19: Relevant clinical trials showed that in the study on the treatment of COVID-19 inpatients with anti-IL-6 receptor antibody tocillizumab, there was no support for the conjecture that “the use of anti-IL-6 drug intervention can improve the symptoms of COVID-19, such as hypoxia and respiratory failure, and reduce the risk of death” (Stone et al., 2020; Declercq et al., 2021).